98%
921
2 minutes
20
The immune response to decellularized extracellular matrix (ECM) muscle injury is characterized by Th2 T cells, Tregs, M2-like macrophages, and an abundance of eosinophils. Eosinophils have previously been described as mediators of muscle regeneration but inhibit skin wound healing. In addition to response to wounding, a large number of eosinophils respond to biomaterial-treated muscle injury, specifically in response to decellularized ECM. ECM treatment of muscle wounds has been associated with positive outcomes in tissue regeneration, but the detailed mechanisms of action are still being evaluated. Here, this work investigates the role of these eosinophils in terms of their immunologic phenotype and subsequent effect on the local tissue microenvironment. These cells have a mixed phenotype showing both type-2 and regulatory gene upregulation and but are not required for macrophage polarization. Beyond the local tissue, ECM treatment is seen to induce a transient flux of eosinophils to the lungs but prevented a trauma-associated neutrophilia in the lungs of injured mice. This work believes this local and systemic immunomodulation contributes to the regenerative effects of the material and such distal tissue effects should be considered in therapeutic design and implementation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834370 | PMC |
http://dx.doi.org/10.1002/adhm.202400134 | DOI Listing |
J Dermatolog Treat
December 2025
Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Background: Bullous pemphigoid (BP) is a common autoimmune subepidermal bullous disease. Dupilumab, an IL-4/IL-13 inhibitor, represents a novel therapeutic approach for BP, but real-world long-term data in super-elderly patients are limited.
Methods: This retrospective, single-center observational study included super-elderly BP patients (≥80 years) receiving dupilumab monotherapy from September 2022 to September 2024.
Clin Gastroenterol Hepatol
September 2025
Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; Gastroenterology Unit, Azienda Ospedale Università Padova, Padua, Italy. Electronic address:
Background And Aims: Topical corticosteroids represent one of the effective first-line treatment options for EoE, and therapy with budesonide orodispersible tablets (BOTs) has been recently approved for the treatment of EoE and showed great efficacy in randomized-controlled clinical trials, however real-life data is lacking. Thus, we aimed to evaluate the effectiveness of treatment with BOTs in adult EoE patients in a real-life setting.
Methods: In this prospective study, clinical, histologic, endoscopic, and safety measures were assessed.
Pol Merkur Lekarski
September 2025
FACULTY OF NURSING, UNIVERSITY OF KUFA, KUFA, IRAQ.
Objective: Aim: To evaluate clinical applicability of immune mediator's interleukin-16, immunoglobulin E along with eosinophil count in diagnosing COVID-19 and determining its severity.
Patients And Methods: Materials and Methods: Cross-sectional case-control study was conducted at Al-Najaf General Hospital, Najaf, Iraq between March and August 2024. 120 participants: 60 confirmed COVID-19 cases and 60 healthy controls which matched cases in terms of age and sex.
J Bras Pneumol
September 2025
. Programa de Pós-Graduação em Ciências Médicas, Universidade Federal de Santa Catarina, Florianópolis (SC) Brasil.
Objective: To describe the impact of severe asthma in a real-life cohort in Brazil, reporting on baseline clinical characteristics, access to treatment, and clinical remission under treatment with biologics.
Methods: Severe asthma patients > 6 years of age were recruited from 23 centers in Brazil. Data on clinical characteristics, lung function, biomarkers, prescribed therapies, and clinical remission under treatment were collected at the baseline visit.
Cureus
August 2025
Internal Medicine, Good Shepherd Hospital, Vythiri, IND.
Hypereosinophilic syndrome (HES) is a rare disorder marked by sustained blood eosinophilia and associated tissue or organ damage in the absence of a secondary identifiable cause. Eosinophilic ascites and pleural effusion are extremely rare clinical presentations of idiopathic HES and often mimic malignancy, tuberculosis, or parasitic infections. We report a case of idiopathic HES in a 68-year-old male presenting with exudative eosinophilic ascites and pleural effusion.
View Article and Find Full Text PDF